[Pregnancy in essential thrombocythemia. Manifestation time and risk for mother and child].
Zahner
J
J
Klinik für Hämatologie, Onkologie und klinische Immunologie, Universität Düsseldorf.
Wehmeier
A
A
Schneider
W
W
D000022:Abortion, Spontaneous / Q000209:etiology; D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D005313:Fetal Death / Q000209:etiology; D006130:Growth Disorders / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D007370:Interferon Type I / Q000627:therapeutic use; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010983:Plateletpheresis; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000175:diagnosis / Q000628:therapy; D011994:Recombinant Proteins; D012189:Retrospective Studies; D013922:Thrombocytosis / Q000175:diagnosis / Q000628:therapy
D007370:Interferon Type I; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D001241:Aspirin
Schwangerschaft bei essentieller Thrombozythämie. Manifestationszeitpunkt und Risiken für Mutter und Kind.